AU2012249851B2 - MicroRNA compounds and methods for modulating miR-21 activity - Google Patents

MicroRNA compounds and methods for modulating miR-21 activity Download PDF

Info

Publication number
AU2012249851B2
AU2012249851B2 AU2012249851A AU2012249851A AU2012249851B2 AU 2012249851 B2 AU2012249851 B2 AU 2012249851B2 AU 2012249851 A AU2012249851 A AU 2012249851A AU 2012249851 A AU2012249851 A AU 2012249851A AU 2012249851 B2 AU2012249851 B2 AU 2012249851B2
Authority
AU
Australia
Prior art keywords
certain embodiments
nucleoside
modified oligonucleotide
mir
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012249851A
Other languages
English (en)
Other versions
AU2012249851A1 (en
AU2012249851A8 (en
Inventor
Balkrishen Bhat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of AU2012249851A1 publication Critical patent/AU2012249851A1/en
Publication of AU2012249851A8 publication Critical patent/AU2012249851A8/en
Application granted granted Critical
Publication of AU2012249851B2 publication Critical patent/AU2012249851B2/en
Priority to AU2017219156A priority Critical patent/AU2017219156B2/en
Assigned to SANOFI reassignment SANOFI Request for Assignment Assignors: Regulus Therapeutics Inc.
Priority to AU2020201403A priority patent/AU2020201403A1/en
Priority to AU2022203067A priority patent/AU2022203067A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
AU2012249851A 2011-04-25 2012-04-25 MicroRNA compounds and methods for modulating miR-21 activity Active AU2012249851B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2017219156A AU2017219156B2 (en) 2011-04-25 2017-08-29 MicroRNA compounds and methods for modulating miR-21 activity
AU2020201403A AU2020201403A1 (en) 2011-04-25 2020-02-26 MicroRNA compounds and methods for modulating miR-21 activity
AU2022203067A AU2022203067A1 (en) 2011-04-25 2022-05-06 MicroRNA compounds and methods for modulating miR-21 activity

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161478767P 2011-04-25 2011-04-25
US61/478,767 2011-04-25
US201161565779P 2011-12-01 2011-12-01
US61/565,779 2011-12-01
PCT/US2012/034880 WO2012148952A1 (en) 2011-04-25 2012-04-25 Microrna compounds and methods for modulating mir-21 activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017219156A Division AU2017219156B2 (en) 2011-04-25 2017-08-29 MicroRNA compounds and methods for modulating miR-21 activity

Publications (3)

Publication Number Publication Date
AU2012249851A1 AU2012249851A1 (en) 2013-10-31
AU2012249851A8 AU2012249851A8 (en) 2013-11-14
AU2012249851B2 true AU2012249851B2 (en) 2017-06-08

Family

ID=46025979

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2012249851A Active AU2012249851B2 (en) 2011-04-25 2012-04-25 MicroRNA compounds and methods for modulating miR-21 activity
AU2017219156A Active AU2017219156B2 (en) 2011-04-25 2017-08-29 MicroRNA compounds and methods for modulating miR-21 activity
AU2020201403A Abandoned AU2020201403A1 (en) 2011-04-25 2020-02-26 MicroRNA compounds and methods for modulating miR-21 activity
AU2022203067A Abandoned AU2022203067A1 (en) 2011-04-25 2022-05-06 MicroRNA compounds and methods for modulating miR-21 activity

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2017219156A Active AU2017219156B2 (en) 2011-04-25 2017-08-29 MicroRNA compounds and methods for modulating miR-21 activity
AU2020201403A Abandoned AU2020201403A1 (en) 2011-04-25 2020-02-26 MicroRNA compounds and methods for modulating miR-21 activity
AU2022203067A Abandoned AU2022203067A1 (en) 2011-04-25 2022-05-06 MicroRNA compounds and methods for modulating miR-21 activity

Country Status (30)

Country Link
US (7) US9181547B2 (enExample)
EP (3) EP2702155B9 (enExample)
JP (2) JP6320292B2 (enExample)
KR (2) KR20190063482A (enExample)
CN (3) CN113249381A (enExample)
AU (4) AU2012249851B2 (enExample)
BR (1) BR112013027187A2 (enExample)
CA (2) CA2833615C (enExample)
CL (1) CL2013003105A1 (enExample)
CO (1) CO6821889A2 (enExample)
CY (1) CY1120304T1 (enExample)
DK (2) DK2702155T3 (enExample)
EA (1) EA025894B1 (enExample)
ES (2) ES2868950T3 (enExample)
HR (2) HRP20170557T2 (enExample)
HU (2) HUE054129T2 (enExample)
IL (3) IL229032B (enExample)
LT (2) LT3211082T (enExample)
MX (5) MX2013012452A (enExample)
MY (2) MY187685A (enExample)
NZ (1) NZ717921A (enExample)
PH (1) PH12013502199A1 (enExample)
PL (2) PL3211082T3 (enExample)
PT (2) PT3211082T (enExample)
RS (1) RS61775B1 (enExample)
SG (1) SG194636A1 (enExample)
SI (2) SI3211082T1 (enExample)
TW (2) TWI698445B (enExample)
UA (1) UA115652C2 (enExample)
WO (1) WO2012148952A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857878A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2012148952A1 (en) 2011-04-25 2012-11-01 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
EP2836219A1 (en) * 2012-04-10 2015-02-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for the treatment of nonalcoholic steatohepatitis
EP2841579B1 (en) * 2012-04-25 2018-10-10 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
SG10201804331TA (en) 2012-11-15 2018-07-30 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
EP2992095B1 (en) 2013-05-01 2019-01-09 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-122
EP3060664B1 (en) * 2013-10-25 2021-07-07 Sanofi Microrna compounds and methods for modulating mir-21 activity
KR101625755B1 (ko) 2013-11-18 2016-05-30 울산대학교 산학협력단 ｍｉＲＮＡ 스폰지 및 이의 용도
JP2017505623A (ja) * 2014-01-30 2017-02-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 生物切断性コンジュゲートを有するポリオリゴマー化合物
CN105734127A (zh) * 2016-02-29 2016-07-06 上海中医药大学 miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
US20190127736A1 (en) 2016-04-29 2019-05-02 Aptamir Therapeutics, Inc. Inhibition of mir-22 mirna by apt-110
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
EP4741512A2 (en) 2017-09-22 2026-05-13 University of Washington In situ combinatorial labeling of cellular molecules
CN108148911B (zh) * 2018-03-02 2019-11-05 广州医科大学附属第二医院 miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用
EP3790972A1 (en) 2018-05-08 2021-03-17 Regulus Therapeutics Inc. Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
CN110747266A (zh) * 2018-07-23 2020-02-04 深圳先进技术研究院 miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) * 2019-03-26 2019-06-14 中国人民解放军第八一医院 一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (en) * 2021-01-29 2022-08-04 Angion Biomedica Corp. Methods for treatment of fibrotic diseases
WO2025110217A1 (ja) * 2023-11-22 2025-05-30 国立大学法人東海国立大学機構 嚢胞性腎疾患の予防及び／又は治療剤
CN120505413A (zh) * 2025-07-15 2025-08-19 湖南工程学院 一种基于引物交换反应和G-四链体检测AKI相关miRNA的探针体系及方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027894A2 (en) * 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
WO2009043353A2 (en) * 2007-10-04 2009-04-09 Santaris Pharma A/S Micromirs
WO2009106367A1 (en) * 2008-02-27 2009-09-03 Julius Maximilians-Universität Würzburg Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ508317A (en) 1998-05-22 2004-01-30 Boys Town Nat Res Hospital Use of alpha1beta1 integrin receptor inhibitors and tgf-beta1 inhibitors in the treatment of kidney disease
US20060008817A1 (en) * 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
CA2462144C (en) 2001-09-28 2016-09-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Micro-rna molecules
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
EP2530157B1 (en) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
JP5192234B2 (ja) 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 化学修飾オリゴヌクレオチド
US20080187508A1 (en) 2004-09-08 2008-08-07 Boys Town National Research Hospital Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
CA2857878A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
US20070099196A1 (en) 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
ES2351674T3 (es) 2006-01-27 2011-02-09 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en la posición 6.
US8129515B2 (en) 2006-01-27 2012-03-06 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
DK2666859T3 (en) 2006-04-03 2019-04-08 Roche Innovation Ct Copenhagen As PHARMACEUTICAL COMPOSITION CONTAINING ANTI-miRNA ANTISENSE OLIGONUCLEOTIDES
EP2261333B1 (en) * 2006-04-03 2016-03-30 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
WO2008042973A2 (en) 2006-10-03 2008-04-10 Alnylam Pharmaceuticals, Inc. Lipid containing formulations
JP2010505427A (ja) 2006-10-09 2010-02-25 ジュリアス−マキシミリアンズ−ユニベルシタット ワーズブルグ 心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ）
WO2008073920A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
US8048998B2 (en) 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2008151631A2 (en) 2007-06-15 2008-12-18 Exiqon A/S Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
EP2176280B2 (en) 2007-07-05 2015-06-24 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
CA2704043C (en) 2007-10-29 2018-09-18 Rosetta Genomics Ltd. Targeting micrornas for the treatment of liver cancer
WO2009091972A2 (en) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
WO2009099326A1 (en) 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
AU2010218147A1 (en) * 2009-02-26 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Dept. Of Health & Human Services MicroRNAs in never-smokers and related materials and methods
AU2010258875A1 (en) * 2009-06-08 2012-01-19 Miragen Therapeutics Chemical modification motifs for miRNA inhibitors and mimetics
WO2011126842A2 (en) 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
WO2012148952A1 (en) 2011-04-25 2012-11-01 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-21 activity
WO2013013165A2 (en) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
EP2841579B1 (en) 2012-04-25 2018-10-10 Regulus Therapeutics Inc. Microrna compounds and methods for modulating mir-21 activity
CN104685056A (zh) 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
EP2900822B1 (en) 2012-09-26 2021-11-24 Guangdong Maijinjia Biotechnology Co., Ltd Oligomers with improved off-target profile
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027894A2 (en) * 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
WO2009043353A2 (en) * 2007-10-04 2009-04-09 Santaris Pharma A/S Micromirs
WO2009106367A1 (en) * 2008-02-27 2009-09-03 Julius Maximilians-Universität Würzburg Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes

Also Published As

Publication number Publication date
CN113249381A (zh) 2021-08-13
PL2702155T3 (pl) 2017-09-29
RS61775B1 (sr) 2021-05-31
IL229032A0 (en) 2013-12-31
AU2017219156A1 (en) 2017-09-21
PT2702155T (pt) 2017-04-03
AU2017219156B2 (en) 2020-01-02
DK3211082T3 (da) 2021-05-10
CN113151272A (zh) 2021-07-23
EP3211082B1 (en) 2021-02-17
ES2621863T9 (es) 2020-02-13
BR112013027187A2 (pt) 2017-06-06
TW201300404A (zh) 2013-01-01
US20140107183A1 (en) 2014-04-17
JP6320292B2 (ja) 2018-05-09
HUE031595T2 (en) 2017-07-28
MX2013012452A (es) 2014-11-21
US20180155719A1 (en) 2018-06-07
MY175336A (en) 2020-06-19
EP2702155A1 (en) 2014-03-05
SG194636A1 (en) 2013-12-30
EP3933040A1 (en) 2022-01-05
US20220098583A1 (en) 2022-03-31
US12331294B2 (en) 2025-06-17
HRP20170557T2 (hr) 2020-02-21
US9181547B2 (en) 2015-11-10
MX2019003090A (es) 2019-07-18
EP3211082A1 (en) 2017-08-30
TWI607016B (zh) 2017-12-01
MX2019003089A (es) 2019-07-18
HK1243130A1 (en) 2018-07-06
PT3211082T (pt) 2021-04-28
US20120270928A1 (en) 2012-10-25
CA2833615C (en) 2022-08-30
AU2022203067A1 (en) 2022-05-26
IL229032B (en) 2021-01-31
MX393138B (es) 2025-03-24
US20160138016A1 (en) 2016-05-19
CL2013003105A1 (es) 2014-08-01
AU2012249851A1 (en) 2013-10-31
US9790496B2 (en) 2017-10-17
HRP20210616T1 (hr) 2021-05-28
US8912161B2 (en) 2014-12-16
PL3211082T3 (pl) 2021-08-02
UA115652C2 (uk) 2017-12-11
JP2018121646A (ja) 2018-08-09
MY187685A (en) 2021-10-11
CN103620035B (zh) 2021-04-23
LT3211082T (lt) 2021-05-10
MX2022000212A (es) 2022-04-01
EP2702155B1 (en) 2017-02-01
CY1120304T1 (el) 2019-07-10
LT2702155T (lt) 2017-05-10
CO6821889A2 (es) 2013-12-31
DK2702155T3 (en) 2017-05-01
KR20190063482A (ko) 2019-06-07
HRP20170557T1 (hr) 2017-06-16
EA201391492A1 (ru) 2014-04-30
US20140329887A1 (en) 2014-11-06
CA3165397A1 (en) 2012-11-01
SI2702155T1 (sl) 2017-07-31
IL273381A (en) 2020-05-31
NZ717921A (en) 2017-09-29
TW201811812A (zh) 2018-04-01
TWI698445B (zh) 2020-07-11
EP2702155B9 (en) 2020-01-01
PH12013502199A1 (en) 2014-01-27
JP2014518619A (ja) 2014-08-07
AU2012249851A8 (en) 2013-11-14
SI3211082T1 (sl) 2021-08-31
AU2020201403A1 (en) 2020-03-12
ES2621863T3 (es) 2017-07-05
IL266529A (en) 2019-07-31
MX2022006595A (es) 2022-07-01
HUE054129T2 (hu) 2021-08-30
ES2868950T3 (es) 2021-10-22
CN103620035A (zh) 2014-03-05
EA025894B1 (ru) 2017-02-28
KR20140033062A (ko) 2014-03-17
US20200291400A1 (en) 2020-09-17
WO2012148952A1 (en) 2012-11-01
NZ616748A (en) 2016-03-31
KR102055172B1 (ko) 2020-01-23
CA2833615A1 (en) 2012-11-01

Similar Documents

Publication Publication Date Title
US12331294B2 (en) MicroRNA compounds and methods for modulating mir-21 activity
US9970009B2 (en) MicroRNA compounds and methods for modulating miR-21 activity
HK40065959A (en) Microrna compounds and methods for modulating mir-21 activity
HK1243130B (en) Microrna compounds and methods for modulating mir-21 activity
HK1195585A (en) Microrna compounds and methods for modulating mir-21 activity
HK1195585B (en) Microrna compounds and methods for modulating mir-21 activity
HK1207115B (en) Microrna compounds and methods for modulating mir-21 activity

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 27 , NO 42 , PAGE(S) 6101 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME REGULUS THERAPEUTICS INC, APPLICATION NO. 2012249851, UNDER INID (54) CORRECT THE TITLE TO MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-21 ACTIVITY

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SANOFI

Free format text: FORMER OWNER(S): REGULUS THERAPEUTICS INC.